MX350195B - Analogos de cistamina para el tratamiento de la enfermedad de parkinson. - Google Patents
Analogos de cistamina para el tratamiento de la enfermedad de parkinson.Info
- Publication number
- MX350195B MX350195B MX2013009608A MX2013009608A MX350195B MX 350195 B MX350195 B MX 350195B MX 2013009608 A MX2013009608 A MX 2013009608A MX 2013009608 A MX2013009608 A MX 2013009608A MX 350195 B MX350195 B MX 350195B
- Authority
- MX
- Mexico
- Prior art keywords
- parkinson
- disease
- cystamine
- treatment
- analogues
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161445577P | 2011-02-23 | 2011-02-23 | |
| CA2732440A CA2732440C (en) | 2011-02-23 | 2011-02-23 | Cystamine analogues for the treatment of parkinson`s disease |
| PCT/CA2012/050106 WO2012113079A1 (en) | 2011-02-23 | 2012-02-23 | Cystamine analogues for the treatment of parkinson's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013009608A MX2013009608A (es) | 2013-09-16 |
| MX350195B true MX350195B (es) | 2017-08-30 |
Family
ID=46717621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013009608A MX350195B (es) | 2011-02-23 | 2012-02-23 | Analogos de cistamina para el tratamiento de la enfermedad de parkinson. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140073694A1 (enExample) |
| EP (1) | EP2678009B1 (enExample) |
| JP (1) | JP6000985B2 (enExample) |
| KR (1) | KR20140115239A (enExample) |
| CN (1) | CN103442704A (enExample) |
| AU (1) | AU2012220314B2 (enExample) |
| BR (1) | BR112013021616A2 (enExample) |
| CA (1) | CA2732440C (enExample) |
| MX (1) | MX350195B (enExample) |
| RU (1) | RU2630583C2 (enExample) |
| WO (1) | WO2012113079A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR096629A1 (es) * | 2013-06-17 | 2016-01-20 | Raptor Pharmaceuticals Inc | Métodos para analizar composiciones de cisteamina |
| TW201618760A (zh) * | 2014-11-05 | 2016-06-01 | 雷普特製藥有限公司 | 使用半胱胺組合物治療亨廷頓氏病之方法 |
| KR20180004756A (ko) | 2015-05-06 | 2018-01-12 | 신애질 코포레이션 | 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법 |
| RU2766579C2 (ru) | 2015-07-02 | 2022-03-15 | ХОРАЙЗОН ОРФАН ЭлЭлСи | Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение |
| US10764961B2 (en) | 2016-03-30 | 2020-09-01 | Guangdong Oppo Mobile Telecommunications Corp., Ltd. | Relay transmission method and device |
| WO2020198529A1 (en) * | 2019-03-26 | 2020-10-01 | The Regents Of The University Ofcalifornia | Substituted amino-thiol and amino-disulfide compounds, and uses thereof |
| US20220265583A1 (en) * | 2019-07-30 | 2022-08-25 | The Regents Of The University Of California | Methods and composition for treating respiratory obstructive diseases |
| CN119909064B (zh) * | 2025-04-07 | 2025-08-15 | 北京大学深圳研究生院 | 胱胺衍生物或其盐以及其在制备具有抗氧化功效的药物中的应用 |
| CN120437102B (zh) * | 2025-07-09 | 2025-09-16 | 中南大学湘雅医院 | 胱胺在制备治疗脓毒症脑病药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060211624A1 (en) * | 2003-02-02 | 2006-09-21 | Goverment of the US, as Represented by | Methods and compositions for the treatment of parkinson's disease and other alpha-synucleinopathies |
| RU2255775C1 (ru) * | 2003-12-25 | 2005-07-10 | Государственное учреждение научно-исследовательский институт неврологии Российской академии медицинских наук | Способ лечения болезни паркинсона |
| CA2640531C (en) * | 2006-01-27 | 2017-01-03 | The Regents Of The University Of California | Enterically coated cysteamine, cystamine and derivatives thereof |
| WO2008143876A2 (en) * | 2007-05-14 | 2008-11-27 | The Trustees Of Columia University In The City Of New York | Agents and assays for modulating neurodegeneration |
| CN102065687A (zh) * | 2008-06-13 | 2011-05-18 | 泰华制药工业有限公司 | 雷沙吉兰用于改善帕金森氏症 |
-
2011
- 2011-02-23 CA CA2732440A patent/CA2732440C/en not_active Expired - Fee Related
-
2012
- 2012-02-23 US US14/000,234 patent/US20140073694A1/en not_active Abandoned
- 2012-02-23 KR KR1020137024680A patent/KR20140115239A/ko not_active Ceased
- 2012-02-23 JP JP2013554768A patent/JP6000985B2/ja not_active Expired - Fee Related
- 2012-02-23 MX MX2013009608A patent/MX350195B/es active IP Right Grant
- 2012-02-23 AU AU2012220314A patent/AU2012220314B2/en not_active Ceased
- 2012-02-23 BR BR112013021616-6A patent/BR112013021616A2/pt not_active IP Right Cessation
- 2012-02-23 CN CN2012800099995A patent/CN103442704A/zh active Pending
- 2012-02-23 EP EP12750124.5A patent/EP2678009B1/en not_active Not-in-force
- 2012-02-23 RU RU2013137645A patent/RU2630583C2/ru not_active IP Right Cessation
- 2012-02-23 WO PCT/CA2012/050106 patent/WO2012113079A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140115239A (ko) | 2014-09-30 |
| AU2012220314B2 (en) | 2017-04-06 |
| US20140073694A1 (en) | 2014-03-13 |
| AU2012220314A1 (en) | 2013-08-22 |
| BR112013021616A2 (pt) | 2020-09-29 |
| EP2678009B1 (en) | 2017-11-01 |
| CA2732440A1 (en) | 2012-08-23 |
| CA2732440C (en) | 2017-10-31 |
| JP2014508758A (ja) | 2014-04-10 |
| CN103442704A (zh) | 2013-12-11 |
| JP6000985B2 (ja) | 2016-10-05 |
| RU2013137645A (ru) | 2015-02-20 |
| RU2630583C2 (ru) | 2017-09-11 |
| WO2012113079A1 (en) | 2012-08-30 |
| EP2678009A1 (en) | 2014-01-01 |
| MX2013009608A (es) | 2013-09-16 |
| EP2678009A4 (en) | 2014-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX350195B (es) | Analogos de cistamina para el tratamiento de la enfermedad de parkinson. | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| MX2010013766A (es) | Rasagilina para modificacion de enfermedad de parkinson. | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| PH12012500968A1 (en) | Use of prostaglandins f2alpha and analogues for the healing of corneal and conjunctival lesions | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| UA113165C2 (xx) | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| MX377576B (es) | Formulaciones de pridopidina de liberación modificada. | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
| MX2015006120A (es) | Compuestos novedosos oralmente biodisponibles que modulan el control de la respiracion, y metodos de uso de los mismos. | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| WO2013085849A3 (en) | Sulfate esters of noribogaine | |
| AU2018253538A1 (en) | Levodopa formulations for rapid relief of parkinson's disease | |
| MX2013008715A (es) | Uso de (s) -esmolol para controlar la irritacion venosa asociada con el tratamiento de un padecimiento cardiaco. | |
| EA201290856A1 (ru) | Стабилизированная фармацевтическая композиция | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| MX2014002817A (es) | Suspension oral. | |
| WO2016025671A3 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
| MY182553A (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| TW201129361A (en) | Methods for treating pain | |
| MX2014011843A (es) | Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |